Tech Company Financing Transactions

Vor Biopharma Funding Round

Vor Biopharma closed a $42 million Series A investment round on 2/15/2019. Investors included 5AM Ventures, RA Capital and Johnson & Johnson Development Corporation.

Transaction Overview

Company Name
Vor Biopharma
Announced On
2/15/2019
Transaction Type
Venture Equity
Amount
$42,000,000
Round
Series A
Investors

5AM Ventures (Lead Investor)

RA Capital (Lead Investor) (Joshua Resnick)

Johnson & Johnson Development Corporation

Novartis BioVenture Fund

Osage Partners

PureTech Ventures (Bharatt Chowrira)

Proceeds Purpose
Vor plans to use the proceeds from the financing to advance its lead HSC-based candidate for the treatment of acute myeloid leukemia (AML) towards the clinic, and to further build its pipeline to treat hematologic malignancies.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
215 1st St. 430
Cambridge, MA 02142
USA
Phone
617-655-6580
Website
www.vorbiopharma.com
Email Address
[email protected]
Overview
Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer. Vor is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.
Profile
Vor Biopharma LinkedIn Company Profile
Social Media
Vor Biopharma Company Twitter Account
Company News
Vor Biopharma News
Facebook
Vor Biopharma on Facebook
YouTube
Vor Biopharma on YouTube

Management Team

Title
Name
Email & Social
Chairman
Siddhartha Mukherjee
  Siddhartha Mukherjee LinkedIn Profile  Siddhartha Mukherjee Twitter Account  Siddhartha Mukherjee News  Siddhartha Mukherjee on Facebook
Chief Executive Officer
Robert Ang
  Robert Ang LinkedIn Profile  Robert Ang Twitter Account  Robert Ang News  Robert Ang on Facebook
Chief Financial Officer
Nathan Jorgensen
  Nathan Jorgensen LinkedIn Profile  Nathan Jorgensen Twitter Account  Nathan Jorgensen News  Nathan Jorgensen on Facebook
Chief Medical Officer
Christopher Slapak
  Christopher Slapak LinkedIn Profile  Christopher Slapak Twitter Account  Christopher Slapak News  Christopher Slapak on Facebook
Chief Technical Officer
Sadik Kassim
  Sadik Kassim LinkedIn Profile  Sadik Kassim Twitter Account  Sadik Kassim News  Sadik Kassim on Facebook
VP - General Counsel
Amy Mendel
  Amy Mendel LinkedIn Profile  Amy Mendel Twitter Account  Amy Mendel News  Amy Mendel on Facebook
VP - Human Resources
Tania Philipp
  Tania Philipp LinkedIn Profile  Tania Philipp Twitter Account  Tania Philipp News  Tania Philipp on Facebook
VP - R & D
Tirtha Chakraborty
  Tirtha Chakraborty LinkedIn Profile  Tirtha Chakraborty Twitter Account  Tirtha Chakraborty News  Tirtha Chakraborty on Facebook
VP - Regulatory Affairs
Robert Pietrusko
  Robert Pietrusko LinkedIn Profile  Robert Pietrusko Twitter Account  Robert Pietrusko News  Robert Pietrusko on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/15/2019: Phylagen venture capital transaction
Next: 2/15/2019: Flow Kana venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.